A flurry of significant insider filings hit this week, with both large-scale buying and heavy selling appearing across multiple sectors.
The biggest buy came from Capital Group, which filed Thursday that it picked up nearly $285 million worth of ONC (BeOne Medicines) shares on May 20. The institutional 5% owner paid around $302 per share for 943,000 shares — a strong vote of confidence in the oncology biotech.
On the sell side, CVS saw the most aggressive dumping. Board-linked hedge fund manager Larry Robbins filed over $296 million in combined sales across May 19–21, unloading nearly 3.2 million shares at prices between $93 and $95. CVS CTO Tilak Mandadi also filed a $6.2 million sale earlier in the month.
TWLO board member Andy Stafman filed a $130.6 million block sale of Twilio stock at $193.54. That's 675,000 shares out the door in a single transaction — notable timing after the stock's strong run this year.
Space and defense firm RDW saw its largest investor, AE Industrial Partners, file an $82 million sale at $14.50. The private equity backer unloaded over 5.6 million shares — a potential signal of profit-taking after Redwire's recent gains.
The divergence is clear: smart money is buying into biotech while trimming positions in healthcare services and high-growth tech. This is not financial advice.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
